CD4 and ovarian carcinoma: However, the CD4+T cell enriched/ CSGALNACT2high group was associated with a better prognosis of ovarian cancer patients, but the CD4+T cell decreased / CSGALNACT2high group predicted poor survival of ovarian cancer patients (Fig. 6B).